Insulet (PODD) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Insulet Corporation (PODD) PT Raised to $53 at Jefferies Following Solid 4Q
February 28, 2017 9:30 AM ESTJefferies raised its price target on Insulet Corporation (NASDAQ: PODD) to $53.00 (from $45.00) while maintaining a Buy rating.
Analyst Raj Denhoy commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13%... More



